biote (BTMD) Competitors

$2.03 -0.17 (-7.73%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$2.05 +0.02 (+0.94%)

As of 05/13/2026 05:53 PM Eastern

BTMD vs. SOPH, CMPX, BCYC, DMAC, and IMRX

Should you buy biote stock or one of its competitors? MarketBeat compares biote with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with biote include SOPHiA GENETICS (SOPH), Compass Therapeutics (CMPX), Bicycle Therapeutics (BCYC), DiaMedica Therapeutics (DMAC), and Immuneering (IMRX). These companies are all part of the "pharmaceutical products" industry.

How does biote compare to SOPHiA GENETICS?

biote (NASDAQ:BTMD) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

21.7% of biote shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 32.4% of biote shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

biote has higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.42	$27.05M	$0.44	4.61
SOPHiA GENETICS	$77.27M	4.00	-$79M	-$0.52	N/A

biote presently has a consensus price target of $2.75, suggesting a potential upside of 35.47%. SOPHiA GENETICS has a consensus price target of $7.50, suggesting a potential upside of 66.30%. Given SOPHiA GENETICS's stronger consensus rating and higher possible upside, analysts plainly believe SOPHiA GENETICS is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

biote has a net margin of 8.29% compared to SOPHiA GENETICS's net margin of -44.48%. biote's return on equity of -25.72% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%

In the previous week, SOPHiA GENETICS had 4 more articles in the media than biote. MarketBeat recorded 5 mentions for SOPHiA GENETICS and 1 mentions for biote. SOPHiA GENETICS's average media sentiment score of 0.31 beat biote's score of -0.13 indicating that SOPHiA GENETICS is being referred to more favorably in the news media.

Company	Overall Sentiment
biote	Neutral
SOPHiA GENETICS	Neutral

biote has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

Summary

biote beats SOPHiA GENETICS on 9 of the 15 factors compared between the two stocks.

How does biote compare to Compass Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

biote has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	417.39	-$66.49M	-$0.41	N/A
biote	$192.22M	0.42	$27.05M	$0.44	4.61

68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by insiders. Comparatively, 32.4% of biote shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

biote has a net margin of 8.29% compared to Compass Therapeutics' net margin of 0.00%. biote's return on equity of -25.72% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-39.75%	-35.29%
biote	8.29%	-25.72%	15.12%

Compass Therapeutics currently has a consensus price target of $13.60, suggesting a potential upside of 590.36%. biote has a consensus price target of $2.75, suggesting a potential upside of 35.47%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Compass Therapeutics is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
biote	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Compass Therapeutics has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, biote has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market.

In the previous week, Compass Therapeutics had 17 more articles in the media than biote. MarketBeat recorded 18 mentions for Compass Therapeutics and 1 mentions for biote. Compass Therapeutics' average media sentiment score of 0.04 beat biote's score of -0.13 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Compass Therapeutics	Neutral
biote	Neutral

Summary

biote beats Compass Therapeutics on 9 of the 17 factors compared between the two stocks.

How does biote compare to Bicycle Therapeutics?

biote (NASDAQ:BTMD) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

biote has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market.

biote presently has a consensus price target of $2.75, suggesting a potential upside of 35.47%. Bicycle Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 195.36%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Bicycle Therapeutics is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

21.7% of biote shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 32.4% of biote shares are owned by company insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

biote has higher revenue and earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.42	$27.05M	$0.44	4.61
Bicycle Therapeutics	$72.86M	4.54	-$218.96M	-$3.15	N/A

In the previous week, Bicycle Therapeutics had 2 more articles in the media than biote. MarketBeat recorded 3 mentions for Bicycle Therapeutics and 1 mentions for biote. Bicycle Therapeutics' average media sentiment score of 1.41 beat biote's score of -0.13 indicating that Bicycle Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
biote	Neutral
Bicycle Therapeutics	Positive

biote has a net margin of 8.29% compared to Bicycle Therapeutics' net margin of -344.95%. biote's return on equity of -25.72% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%

Summary

biote beats Bicycle Therapeutics on 9 of the 16 factors compared between the two stocks.

How does biote compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

DiaMedica Therapeutics has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, biote has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market.

biote has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
biote	$192.22M	0.42	$27.05M	$0.44	4.61

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by company insiders. Comparatively, 32.4% of biote shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, DiaMedica Therapeutics had 13 more articles in the media than biote. MarketBeat recorded 14 mentions for DiaMedica Therapeutics and 1 mentions for biote. biote's average media sentiment score of -0.13 beat DiaMedica Therapeutics' score of -0.28 indicating that biote is being referred to more favorably in the news media.

Company	Overall Sentiment
DiaMedica Therapeutics	Neutral
biote	Neutral

DiaMedica Therapeutics currently has a consensus target price of $12.33, indicating a potential upside of 97.02%. biote has a consensus target price of $2.75, indicating a potential upside of 35.47%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe DiaMedica Therapeutics is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
biote	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

biote has a net margin of 8.29% compared to DiaMedica Therapeutics' net margin of 0.00%. biote's return on equity of -25.72% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
biote	8.29%	-25.72%	15.12%

Summary

biote beats DiaMedica Therapeutics on 11 of the 15 factors compared between the two stocks.

How does biote compare to Immuneering?

biote (NASDAQ:BTMD) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

biote has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

21.7% of biote shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 32.4% of biote shares are owned by company insiders. Comparatively, 22.9% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

biote has a net margin of 8.29% compared to Immuneering's net margin of 0.00%. biote's return on equity of -25.72% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
Immuneering	N/A	-43.33%	-39.75%

biote currently has a consensus target price of $2.75, indicating a potential upside of 35.47%. Immuneering has a consensus target price of $16.50, indicating a potential upside of 206.69%. Given Immuneering's stronger consensus rating and higher possible upside, analysts clearly believe Immuneering is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

biote has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.42	$27.05M	$0.44	4.61
Immuneering	N/A	N/A	-$56.03M	-$1.38	N/A

In the previous week, Immuneering had 1 more articles in the media than biote. MarketBeat recorded 2 mentions for Immuneering and 1 mentions for biote. Immuneering's average media sentiment score of 0.97 beat biote's score of -0.13 indicating that Immuneering is being referred to more favorably in the news media.

Company	Overall Sentiment
biote	Neutral
Immuneering	Positive

Summary

biote beats Immuneering on 9 of the 16 factors compared between the two stocks.

Get biote News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTMD vs. The Competition

Export

Metric	biote	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$87.01M	$8.12B	$6.30B	$12.20B
Dividend Yield	N/A	2.50%	2.79%	5.30%
P/E Ratio	4.61	18.19	21.00	25.58
Price / Sales	0.42	7.65	554.55	78.84
Price / Cash	3.79	16.76	42.94	55.34
Price / Book	-1.68	3.75	9.75	6.66
Net Income	$27.05M	$223.05M	$3.55B	$333.63M
7 Day Performance	-2.87%	-2.05%	-0.53%	-0.11%
1 Month Performance	9.14%	3.40%	1.20%	3.94%
1 Year Performance	-48.48%	1.89%	41.22%	36.07%

biote Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTMD biote	3.8326 of 5 stars	$2.03 -7.7%	$2.75 +35.5%	-48.1%	$87.01M	$192.22M	4.61	194
SOPH SOPHiA GENETICS	2.6106 of 5 stars	$5.09 -3.8%	$7.50 +47.3%	+44.6%	$349.92M	$77.27M	N/A	520	Gap Down
CMPX Compass Therapeutics	3.0982 of 5 stars	$1.93 -0.8%	$13.60 +606.5%	-1.5%	$344.87M	$850K	N/A	20
BCYC Bicycle Therapeutics	3.554 of 5 stars	$4.86 -1.6%	$14.00 +187.9%	-41.6%	$339.13M	$63.50M	N/A	240
DMAC DiaMedica Therapeutics	1.2961 of 5 stars	$6.27 +3.6%	$12.33 +96.8%	+57.3%	$337.42M	N/A	N/A	20	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTMD) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

biote (BTMD) Competitors

BTMD vs. SOPH, CMPX, BCYC, DMAC, and IMRX

How does biote compare to SOPHiA GENETICS?

Summary

How does biote compare to Compass Therapeutics?

Summary

How does biote compare to Bicycle Therapeutics?

Summary

How does biote compare to DiaMedica Therapeutics?

Summary

How does biote compare to Immuneering?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTMD vs. The Competition

biote Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

biote (BTMD) Competitors

BTMD vs. SOPH, CMPX, BCYC, DMAC, and IMRX

How does biote compare to SOPHiA GENETICS?

Do institutionals and insiders have more ownership in BTMD or SOPH?

Which has higher valuation & earnings, BTMD or SOPH?

Do analysts rate BTMD or SOPH?

Is BTMD or SOPH more profitable?

Does the media refer more to BTMD or SOPH?

Which has more risk and volatility, BTMD or SOPH?

Summary

How does biote compare to Compass Therapeutics?

Which has preferable earnings & valuation, CMPX or BTMD?

Do institutionals & insiders have more ownership in CMPX or BTMD?

Is CMPX or BTMD more profitable?

Do analysts prefer CMPX or BTMD?

Which has more volatility & risk, CMPX or BTMD?

Does the media favor CMPX or BTMD?

Summary

How does biote compare to Bicycle Therapeutics?

Which has more risk & volatility, BTMD or BCYC?

Do analysts recommend BTMD or BCYC?

Do institutionals and insiders hold more shares of BTMD or BCYC?

Which has better valuation and earnings, BTMD or BCYC?

Does the media refer more to BTMD or BCYC?

Is BTMD or BCYC more profitable?

Summary

How does biote compare to DiaMedica Therapeutics?

Which has more volatility and risk, DMAC or BTMD?

Which has higher valuation and earnings, DMAC or BTMD?

Do insiders and institutionals believe in DMAC or BTMD?

Does the media favor DMAC or BTMD?

Do analysts rate DMAC or BTMD?

Is DMAC or BTMD more profitable?

Summary

How does biote compare to Immuneering?

Which has more volatility & risk, BTMD or IMRX?

Do institutionals and insiders believe in BTMD or IMRX?

Is BTMD or IMRX more profitable?

Do analysts recommend BTMD or IMRX?

Which has higher earnings & valuation, BTMD or IMRX?

Does the media refer more to BTMD or IMRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTMD vs. The Competition

biote Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools